Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?

被引：147
作者：
Asselah, Tarik [1 ]
Marcellin, Patrick [1 ]
Schinazi, Raymond F. [2 ]
机构：
[1] Univ Paris Diderot, Ctr Rech Inflammat, Hop Beaujon, AP HP,Dept Hepatol,Viral Hepatitis INSERM,UMR 114, Clichy, France
[2] Emory Univ, Sch Med, Dept Pediat, Ctr AIDS Res, Atlanta, GA USA
来源：
LIVER INTERNATIONAL | 2018年 / 38卷
关键词：
chronic hepatitis C; compliance; genotype; HCV elimination; people who inject drugs; screening; GENOTYPE; 1; INFECTION; TREATMENT-NAIVE; HCV; SOFOSBUVIR; VELPATASVIR; PIBRENTASVIR; VOXILAPREVIR; GLECAPREVIR; ELBASVIR; THERAPY;
D O I：
10.1111/liv.13673
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Around 71 million people are chronically infected with HCV worldwide. HCV antiviral drug development has been remarkable. The availability of pangenotypic direct-acting antivirals with excellent efficacy and good tolerability profiles offer a unique opportunity to achieve HCV elimination worldwide. IFN-free DAA combinations can now cure HCV in more than 95% of patients with HCV infection after 8-12weeks of treatment. Programmes to eliminate HCV must include increased screening (risk-based and universal), linkage to care, as well as increased access to treatment worldwide. In this paper, we will review the available data on recently approved direct-acting antiviral agents, with sustained virological response that reaches almost 100%.
引用
收藏
页码：7 / 13
页数：7
相关论文
共 26 条
[1]   Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension [J].
Afdhal, N. ;
Everson, G. T. ;
Calleja, J. L. ;
McCaughan, G. W. ;
Bosch, J. ;
Brainard, D. M. ;
McHutchison, J. G. ;
De-Oertel, S. ;
An, D. ;
Charlton, M. ;
Reddy, K. R. ;
Asselah, T. ;
Gane, E. ;
Curry, M. P. ;
Forns, X. .
JOURNAL OF VIRAL HEPATITIS, 2017, 24 (10) :823-831
[2]  
Asante-Appiah E, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.00363-17, 10.1128/AAC.00363-17]
[3]  
Asselah T, 2018, CLIN GASTRO IN PRESS
[4]  
Asselah T, 66 ANN M AM ASS STUD
[5]  
Asselah T, 2018, LIVER INT IN PRESS
[6]   Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives [J].
Asselah, Tarik ;
Boyer, Nathalie ;
Saadoun, David ;
Martinot-Peignoux, Michele ;
Marcellin, Patrick .
LIVER INTERNATIONAL, 2016, 36 :47-57
[7]   Sofosbuvir for the treatment of hepatitis C virus [J].
Asselah, Tarik .
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (01) :121-130
[8]   Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection [J].
Bourliere, M. ;
Gordon, S. C. ;
Flamm, S. L. ;
Cooper, C. L. ;
Ramji, A. ;
Tong, M. ;
Ravendhran, N. ;
Vierling, J. M. ;
Tran, T. T. ;
Pianko, S. ;
Bansal, M. B. ;
Ledinghen, V. de ;
Hyland, R. H. ;
Stamm, L. M. ;
Dvory-Sobol, H. ;
Svarovskaia, E. ;
Zhang, J. ;
Huang, K. C. ;
Subramanian, G. M. ;
Brainard, D. M. ;
McHutchison, J. G. ;
Verna, E. C. ;
Buggisch, P. ;
Landis, C. S. ;
Younes, Z. H. ;
Curry, M. P. ;
Strasser, S. I. ;
Schiff, E. R. ;
Reddy, K. R. ;
Manns, M. P. ;
Kowdley, K. V. ;
Zeuzem, S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (22) :2134-2146
[9]   GS-5816, A SECOND GENERATION HCV NS5A INHIBITOR WITH POTENT ANTIVIRAL ACTIVITY, BROAD GENOTYPIC COVERAGE AND A HIGH RESISTANCE BARRIER [J].
Cheng, G. ;
Yu, M. ;
Peng, B. ;
Lee, Y. -J. ;
Trejo-Martin, A. ;
Gong, R. ;
Bush, C. ;
Worth, A. ;
Nash, M. ;
Chan, K. ;
Yang, H. ;
Beran, R. ;
Tian, Y. ;
Perry, J. ;
Taylor, J. ;
Yang, C. ;
Paulson, M. ;
Delaney, W. ;
Link, J. O. .
JOURNAL OF HEPATOLOGY, 2013, 58 :S484-S485
[10]   Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis [J].
Curry, M. P. ;
O'Leary, J. G. ;
Bzowej, N. ;
Muir, A. J. ;
Korenblat, K. M. ;
Fenkel, J. M. ;
Reddy, K. R. ;
Lawitz, E. ;
Flamm, S. L. ;
Schiano, T. ;
Teperman, L. ;
Fontana, R. ;
Schiff, E. ;
Fried, M. ;
Doehle, B. ;
An, D. ;
McNally, J. ;
Osinusi, A. ;
Brainard, D. M. ;
McHutchison, J. G. ;
Brown, R. S., Jr. ;
Charlton, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) :2618-2628
123